Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss

Cancer therapies that simultaneously target activated mammalian target of rapamycin (mTOR) and cell metabolism are urgently needed. The goal of our study was to identify therapies that effectively inhibited both mTOR activity and cancer cell metabolism in primary tumors in vivo. Using our mouse mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrade-Vieira, Rafaela, Goguen, Donna, Bentley, Heidi A., Bowen, Chris V., Marignani, Paola A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350354/
https://www.ncbi.nlm.nih.gov/pubmed/25436981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350354/
https://www.ncbi.nlm.nih.gov/pubmed/25436981

Ejemplares similares